Browsing Tag
Bristol Myers Squibb
58 posts
Beeline Medicines advances afimetoran toward pivotal lupus trials after strong Phase 2 results
Beeline Medicines' afimetoran trial success puts its $426.3 million-backed lupus strategy in focus. Explore the pivotal plans and risks ahead.
Why ArsenalBio is cutting 99 jobs two years after its $325m Series C
Arsenal Biosciences is eliminating 99 jobs, representing a majority of employees across functions and locations, as the well-funded biotech pivots from its autologous solid-tumor CAR-T strategy toward in vivo cell therapy for blood cancers and autoimmune disease.
Why Cellares is cutting 100 jobs after Bristol Myers ends $380m CAR-T deal
Cellares will permanently eliminate 100 South San Francisco positions after Bristol Myers Squibb terminated a manufacturing partnership worth up to $380 million, saying the Cell Shuttle platform could not meet commercial Breyanzi requirements, an assessment Cellares disputes.
Myqorzo could expand across the HCM spectrum after Cytokinetics delivers pivotal ACACIA-HCM results
Cytokinetics plans an FDA filing after aficamten succeeds in non-obstructive HCM. See what ACACIA-HCM could mean for Myqorzo growth.
Oxford Biomedica (LSE: OXB) plunges 15% as 2026 revenue guidance falls
Oxford Biomedica cut 2026 revenue guidance by £40m at midpoint. September results must show whether OXB’s setback is timing or something deeper.
Braveheart Bio IPO targets $1.2bn valuation as HCM drug race heats up
Braveheart Bio is seeking up to $318.8 million in its Nasdaq IPO, but investors must decide whether its cardiac myosin inhibitor can compete in an increasingly crowded hypertrophic cardiomyopathy market.
Cytokinetics secures UK approval and NHS access for aficamten in obstructive HCM
UK approval and NICE reimbursement give aficamten access to 6,600 patients as Cytokinetics expands its global HCM commercial launch.
![Ratio Therapeutics’ $70 million Series C financing will support the ATLAS trial of [Ac-225]RTX-2358, expand its targeted radiotherapeutics pipeline and strengthen radiopharmaceutical manufacturing capacity. Representative image.](https://business-news-today.com/wp-content/uploads/2026/07/Ratio-Therapeutics-raises-70-million-to-advance-ATLAS-trial-and-radiopharmaceutical-manufacturing-380x280.png)
Can Ratio Therapeutics turn a $70m funding round into a scalable cancer-treatment platform?
Ratio Therapeutics’ Series C financing gives the Boston oncology company additional capital to advance [Ac-225]RTX-2358, bring another radioligand therapy into clinical development and expand the manufacturing network needed to support a broader cancer pipeline.
Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites
Scalp and palmoplantar clearance rates approached 70% to 77%, but regulatory review, safety labelling and market access will determine the commercial impact.
Ipsen to buy Kartos Therapeutics for up to $1.75bn as IPN nears 52-week high
Ipsen is buying Kartos for up to $1.75 billion. Read how navtemadlin could reshape its oncology pipeline, earnings outlook and IPN valuation after the deal.